FDA clears APP Pharma's generics

02/10/2008 | Boston Globe (tiered subscription model), The

Schaumburg, Ill.-based APP Pharmaceuticals on Friday announced that the FDA has cleared its Caffeine Citrate Oral Solution at 20 mg/ml for the short-term treatment of apnea in premature infants and its injectable bleomycin sulfate for use in combination with other cancer medications. The drugs are generic equivalents of Bedford Laboratories' Cafcit Oral Solution and Bristol-Myers Squibb Co.'s Blenoxane, respectively.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA